Oriol Grau-Rivera

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4660241/publications.pdf

Version: 2024-02-01

75 papers	1,825 citations	236925 25 h-index	289244 40 g-index
76 all docs	76 docs citations	76 times ranked	3583 citing authors

#	Article	IF	Citations
1	Genotypic effects ofAPOE-Îµ4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. Cerebral Cortex, 2023, 33, 2748-2760.	2.9	5
2	Soundtrack of life: An fMRI study. Behavioural Brain Research, 2022, 418, 113634.	2.2	0
3	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
4	Brain alterations in the early Alzheimerâ€™s continuum with amyloid-Î², tau, glial and neurodegeneration CSF markers. Brain Communications, 2022, 4, .	3.3	12
5	DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease. American Journal of Clinical Nutrition, 2021, 113, 1627-1635.	4.7	17
6	Amyloid-Î² positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. Neurobiology of Aging, 2021, 104, 24-31.	3.1	13
7	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. Neurology, 2021, 97, e2065-e2078.	1.1	40
8	Associations between air pollution and biomarkers of Alzheimerâ€™s disease in cognitively unimpaired individuals. Environment International, 2021, 157, 106864.	10.0	40
9	Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloidâ€positive individuals with subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.8	1
10	Subjective cognitive decline is associated with higher anxiety and depression during the COVIDâ€19â€related confinement. Alzheimer's and Dementia, 2021, 17, .	0.8	1
11	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimerâ€™s continuum. Alzheimer's and Dementia, 2021, 17, .	0.8	2
12	Crossâ€sectional associations between sleep quality reports and core Alzheimerâ€™s disease biomarkers in cognitively unimpaired adults from the European Prevention of Alzheimerâ€™s Dementia Longitudinal Cohort Study (EPAD LCS). Alzheimer's and Dementia, 2021, 17, .	0.8	0
13	Distinctive effect of biological sex in ADâ€related CSF and plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.8	2
14	Dataâ€driven approach for early detection of pathological pathways in middleâ€aged adults with family history of sporadic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
15	Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching Î²â€amyloid biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.8	0
16	Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
17	Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middleâ€aged adults with and without evidence of Î²â€amyloid pathology. Alzheimer's and Dementia, 2021, 17, .	0.8	0
18	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	Article	IF	Citations
19	Sex, caregiver status and amyloid positivity predict increased anxiety and depression during the COVIDâ€19â€related confinement. Alzheimer's and Dementia, 2021, 17, .	0.8	0
20	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. Brain Imaging and Behavior, 2020, 14, 2012-2023.	2.1	40
21	Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. Alzheimer's Research and Therapy, 2020, 12, 4.	6.2	53
22	White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. Human Brain Mapping, 2020, 41, 1309-1322.	3.6	27
23	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. Journal of Alzheimer's Disease, 2020, 76, 1413-1422.	2.6	4
24	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. Neurology, 2020, 95, e2065-e2074.	1.1	3
25	Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-Îµ4 in middle-age cognitively unimpaired individuals from the ALFA study. Brain Structure and Function, 2020, 225, 2331-2345.	2.3	5
26	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimerâ€™s continuum when only subtle changes in AÎ² pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	6.9	202
27	Amyloidâ€Îβ, tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimerâ€™s continuum. Alzheimer's and Dementia, 2020, 16, e044444.	0.8	0
28	Emerging betaâ€amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. Alzheimer's and Dementia, 2020, 16, e044466.	0.8	1
29	Genetically predicted telomere length and Alzheimerâ€™s disease endophenotypes: A Mendelian randomization study. Alzheimer's and Dementia, 2020, 16, e044720.	0.8	0
30	The effect of physical activity on CSF biomarkers of Alzheimerâ€™s disease differs between men and women. Alzheimer's and Dementia, 2020, 16, e044722.	0.8	0
31	Air pollution and biomarkers of Alzheimerâ€™s disease in cognitively unimpaired individuals. Alzheimer's and Dementia, 2020, 16, e044802.	0.8	3
32	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044808.	0.8	0
33	APOE â€Îµ4 shapes temporoâ€parietal network properties in middleâ€aged, cognitively unimpaired individuals: A graph theory analysis. Alzheimer's and Dementia, 2020, 16, e045092.	0.8	0
34	Weight loss predicts Alzheimerâ€™s disease biomarker positivity in cognitively unimpaired middleâ€aged adults. Alzheimer's and Dementia, 2020, 16, e045137.	0.8	0
35	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. Alzheimer's and Dementia, 2020, 16, e045171.	0.8	0
36	Incidence of subjective cognitive decline is associated with amyloidâ€Îβ pathology, whereas stability relates to neurodegeneration. Alzheimer's and Dementia, 2020, 16, e045293.	0.8	0

#	Article	IF	Citations
37	Amyloidâ€positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. Alzheimer's and Dementia, 2020, 16, e045715.	0.8	0
38	The Barcelonabeta dementia prevention research clinic: Study design, recruitment profiles and inclusion in prevention studies â€" An update. Alzheimer's and Dementia, 2020, 16, e045800.	0.8	0
39	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, 1358-1371.	0.8	120
40	Copathology in Progressive Supranuclear Palsy: Does It Matter?. Movement Disorders, 2020, 35, 984-993.	3.9	48
41	A unique common ancestor introduced P301L mutation in MAPT gene in frontotemporal dementia patients from Barcelona (Baix Llobregat, Spain). Neurobiology of Aging, 2019, 84, 236.e9-236.e15.	3.1	7
42	Interactive effect of age and APOE-Îµ4 allele load on white matter myelin content in cognitively normal middle-aged subjects. NeuroImage: Clinical, 2019, 24, 101983.	2.7	30
43	Spatial patterns of white matter hyperintensities associated with Alzheimerâ€™s disease risk factors in a cognitively healthy middle-aged cohort. Alzheimer's Research and Therapy, 2019, 11, 12.	6.2	46
44	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research and Therapy, 2019, 11, 27.	6.2	82
45	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. NeuroImage: Clinical, 2019, 23, 101801.	2.7	26
46	Structural Connectivity Alterations Along the Alzheimerâ€™s Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-Î² and Tau. Journal of Alzheimer's Disease, 2018, 61, 1575-1587.	2.6	25
47	Tauopathy with Hippocampal 4â€Repeat Tau Immunoreactive Spherical Inclusions in a Patient with PSP. Brain Pathology, 2018, 28, 284-286.	4.1	4
48	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 162-168.	1.9	44
49	Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. Alzheimer's Research and Therapy, 2018, 10, 123.	6.2	73
50	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
51	Variably proteaseâ€sensitive prionopathy presenting within ALS/FTD spectrum. Annals of Clinical and Translational Neurology, 2018, 5, 1297-1302.	3.7	10
52	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. Journal of Alzheimer's Disease, 2018, 65, 181-191.	2.6	15
53	White matter microstructure is altered in cognitively normal middle-aged APOE-Îµ4 homozygotes. Alzheimer's Research and Therapy, 2018, 10, 48.	6.2	43
54	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. Journal of Neuropathology and Experimental Neurology, 2018, 77, 703-709.	1.7	18

#	Article	IF	Citations
55	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimerâ€™s disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
56	Regional Overlap of Pathologies in Lewy Body Disorders. Journal of Neuropathology and Experimental Neurology, 2017, 76, 216-224.	1.7	45
57	Frontotemporal Dementia Caused by the P301L Mutation in the<i> MAPT</i> Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. Dementia and Geriatric Cognitive Disorders, 2017, 44, 213-221.	1.5	31
58	Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. Brain, 2017, 140, e51-e51.	7.6	43
59	Conjoint FTLDâ€FUS of the neuronal intermediate filament inclusion disease type, progressive supranuclear palsy and Alzheimer's pathology presenting as parkinsonism with early falls and late hallucinations, psychosis and dementia. Neuropathology and Applied Neurobiology, 2017, 43, 352-357.	3.2	2
60	Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. Frontiers in Neurology, 2017, 8, 89.	2.4	35
61	Clinical Neuropathology image 4-2017: High-resolution 7 Tesla MRI of postmortem brain specimens: improving neuroimaging-neuropathology correlations. , 2017, 36, 162-163.		1
62	Altered mechanisms of protein synthesis in frontal cortex in Alzheimer disease and a mouse model. American Journal of Neurodegenerative Disease, 2017, 6, 15-25.	0.1	19
63	Pisa syndrome in a patient with pathologically confirmed Parkinson's disease. Neuropathology and Applied Neurobiology, 2016, 42, 654-658.	3.2	6
64	Sporadic MM2â€thalamicâ€‰+â€‰cortical Creutzfeldtâ€Jakob disease: Utility of diffusion tensor imaging in the detection of cortical involvement in vivo. Neuropathology, 2016, 36, 199-204.	1.2	11
65	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. Journal of Alzheimer's Disease, 2016, 55, 431-443.	2.6	17
66	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 213-224.	7.7	83
67	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Neurodegenerative Diseases, 2016, 16, 69-76.	1.4	36
68	Clinicopathological Correlations and Concomitant Pathologies in Rapidly Progressive Dementia: A Brain Bank Series. Neurodegenerative Diseases, 2015, 15, 350-360.	1.4	35
69	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. Neuropathology and Applied Neurobiology, 2015, 41, 882-892.	3.2	26
70	Subtype and regional regulation of prion biomarkers in sporadic <scp>C</scp>reutzfeldtâ€“<scp>J</scp>akob disease. Neuropathology and Applied Neurobiology, 2015, 41, 631-645.	3.2	24
71	Rapidly progressive dementia with psychotic onset in a patient with the C9ORF72 mutation. , 2015, 34, 294-297.		7
72	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 74.	9.0	59

#	Article	IF	Citations
73	Large APP locus duplication in a sporadic case of cerebral haemorrhage. Neurogenetics, 2014, 15, 145-149.	1.4	12
74	Prominent psychiatric symptoms in patients with Parkinsonâ€™s disease and concomitant argyrophilic grain disease. Journal of Neurology, 2013, 260, 3002-3009.	3.6	15
75	PrP mRNA and protein expression in brain and PrPcin CSF in Creutzfeldt-Jakob disease MM1 and VV2. Prion, 2013, 7, 383-393.	1.8	45